An increased risk of both invasive and superficial fungal infections was observed among patients who received TNF-α inhibitors for various conditions.

The use of TNF inhibitors was not linked to worse survival outcomes among patients with rheumatoid arthritis during the 3 years after being diagnosed with lung, colorectal, or prostate cancer.

Therefore, researchers conducted a retrospective case-control study comparing cancer risks among patients with RA who received JAK inhibitors, tumor necrosis factor (TNF) inhibitors, and other ...

and non-melanoma skin cancer (NMSC), was observed with tofacitinib compared to tumour necrosis factor (TNF) inhibitors. A higher rate of malignancies, including NMSC, was observed with RINVOQ 30 ...

Vedolizumab as a first-line biologic in UC offers cost savings and clinical benefits, improving QALYs compared to TNF-α inhibitors. In CD, vedolizumab provides incremental benefits but incurs ...

A rash on the inner thigh or near the groin can be caused by close-fitting clothing, leg shaving, or situations that result in little airflow and sweat that can trigger a rash. Common skin disorders ...

particularly with tumor necrosis factor (TNF) inhibitors and IL-17/23 inhibitors. 2,3 Similarly, this study aimed to investigate sex-specific differences in drug survival and other treatment ...

Biological and targeted synthetic DMARDs were split into five classes: TNF inhibitors, interleukin (IL)-6 inhibitors, JAK inhibitors, rituximab (Rituxan, Genentech) and abatacept (Orencia ...

Biological therapies have revolutionized treatment outcomes, with tumor necrosis factor inhibitors demonstrating efficacy for both skin and joint manifestations. Newer targeted therapies including ...

The study assessed the risk of hospitalisation for serious infections based on different categories of systemic medications, including methotrexate, other older systemic drugs, tumour necrosis factor ...

Finally, the oral tumor necrosis factor (TNF) inhibitor SAR441566 has begun clinical evaluation outside the U.S. for patients with psoriasis and rheumatoid arthritis. The first clinical results ...